MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
Aptevo Therapeutics Retained Earnings 2011-2025 | APVO
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Aptevo Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -248 M | -223 M | -206 M | -214 M | - | -168 M | -127 M | -73.7 M | -80.7 M | -232 M | -173 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -73.7 M | -248 M | -175 M |
Quarterly Retained Earnings Aptevo Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -269 M | -260 M | -254 M | -248 M | -241 M | -236 M | -230 M | -223 M | -218 M | -211 M | -203 M | -206 M | -201 M | -194 M | -222 M | -214 M | -208 M | -201 M | -193 M | -186 M | -186 M | -186 M | -186 M | -168 M | -168 M | -168 M | -168 M | -127 M | -127 M | -127 M | -127 M | -73.7 M | -73.7 M | -73.7 M | -73.7 M | -80.7 M | -80.7 M | -80.7 M | -80.7 M | -232 M | -232 M | -232 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -73.7 M | -269 M | -178 M |
Retained Earnings of other stocks in the Biotechnology industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Arbutus Biopharma Corporation
ABUS
|
-1.28 B | $ 4.95 | 4.99 % | $ 822 M |  Canada |
 |
MorphoSys AG
MOR
|
-158 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aclaris Therapeutics
ACRS
|
-903 M | $ 3.2 | -1.48 % | $ 247 M |  USA |
 |
AlloVir
ALVR
|
-715 M | - | 4.14 % | $ 49.1 M | USA |
 |
Catalyst Biosciences
CBIO
|
-85.5 M | $ 13.19 | -6.39 % | $ 868 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.24 B | - | - | $ 40.3 B | USA |
 |
Ascendis Pharma A/S
ASND
|
-611 M | $ 213.99 | -2.92 % | $ 5 B |  Danmark |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-108 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
-122 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alterity Therapeutics Limited
ATHE
|
-182 M | $ 3.1 | -5.93 % | $ 7.46 B |  Australia |
 |
Celldex Therapeutics
CLDX
|
-1.56 B | $ 27.04 | -1.73 % | $ 1.74 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
544 M | $ 87.29 | -0.8 % | $ 9.01 B | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
285 M | $ 24.46 | 3.56 % | $ 2.9 B | USA |
 |
CureVac N.V.
CVAC
|
-1.06 B | $ 5.04 | -0.3 % | $ 938 M | Germany |
 |
Biophytis SA
BPTS
|
-17.1 M | - | -13.47 % | $ 169 M |  France |
 |
Институт стволовых клеток человека
ISKJ
|
69.4 M | - | - | - |  Russia |
 |
BioVie
BIVI
|
-352 M | $ 1.43 | -1.38 % | $ 2.11 M | USA |
 |
ARCA biopharma
ABIO
|
-83.7 M | - | 1052.0 % | $ 415 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
-903 M | $ 10.87 | 0.63 % | $ 1.41 B | USA |
 |
Acasti Pharma
ACST
|
-221 M | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
-1.02 B | - | -15.15 % | $ 60.3 M | Britain |
 |
BioNTech SE
BNTX
|
-410 M | $ 94.19 | -0.66 % | $ 27.2 B | Germany |
 |
Aeglea BioTherapeutics
AGLE
|
-972 M | - | - | $ 1.01 B | USA |
 |
Albireo Pharma
ALBO
|
-301 M | - | -0.23 % | $ 916 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-224 M | - | - | $ 2.17 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-243 M | - | -11.43 % | $ 502 K | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
569 M | $ 26.28 | 4.0 % | $ 1.27 B | USA |
 |
Applied Molecular Transport
AMTI
|
-366 M | - | - | $ 10.1 M | USA |
 |
Anika Therapeutics
ANIK
|
128 M | $ 9.64 | 0.84 % | $ 141 M | USA |
 |
Eton Pharmaceuticals
ETON
|
-104 M | $ 15.96 | -4.43 % | $ 409 M | USA |
 |
Evogene Ltd.
EVGN
|
-179 M | $ 1.05 | -2.78 % | $ 27.9 M |  Israel |
 |
Can-Fite BioPharma Ltd.
CANF
|
-166 M | $ 0.27 | -6.29 % | $ 588 M | Israel |
|
Foghorn Therapeutics
FHTX
|
-558 M | $ 4.39 | -1.13 % | $ 241 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
-2.12 B | - | -6.81 % | $ 3.04 B | USA |
 |
Athersys
ATHX
|
-583 M | - | 3.77 % | $ 22.4 M | USA |
 |
Acer Therapeutics
ACER
|
-141 M | - | 2.71 % | $ 14 M | USA |
 |
Avenue Therapeutics
ATXI
|
-103 M | - | -52.27 % | $ 4.45 M | USA |
 |
AVROBIO
AVRO
|
-477 M | - | 1083.1 % | $ 745 M | USA |
 |
Axon Enterprise
AXON
|
812 M | $ 548.77 | -2.75 % | $ 41.6 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-149 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
-334 M | $ 2.36 | 2.61 % | $ 14.8 M | USA |
 |
AstraZeneca PLC
AZN
|
5.3 B | $ 91.51 | 1.87 % | $ 96.9 B | Britain |
 |
Acorda Therapeutics
ACOR
|
-1.19 B | - | -24.86 % | $ 820 K | USA |
 |
Brickell Biotech
BBI
|
-172 M | - | -5.38 % | $ 6.06 M | USA |
 |
BeiGene, Ltd.
BGNE
|
-8.61 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
-2.59 B | $ 11.28 | -2.17 % | $ 730 M | USA |
 |
Biogen
BIIB
|
19.3 B | $ 174.19 | 0.05 % | $ 25.4 B | USA |
 |
Abeona Therapeutics
ABEO
|
-750 M | $ 5.07 | -5.5 % | $ 108 M | USA |